The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
An [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s disease
Open accessAbstract
We have studied disease progression in a group of 10 patients with recent onset idiopathic Parkinson's disease [mean age 53.7 +/- 12.6 years, mean duration 18.3 +/- 6.5 months, mean unified Parkinson's disease rating scale (UPDRS) 19.0 +/- 9.5], and a group of seven patients with established Parkinson's disease (mean age 60.1 +/- 15.1 years, mean duration 70.8 +/- 35.5 months, mean UPDRS 47.9 +/- 18.1), using both clinical assessment and [18F]dopa-PET. Results were compared with those of a group of 10 normal subjects (age 66 +/- 16 years). Mean putamen [18F]dopa influx constant (Ki) was a reliable measurement (R = 0.82) and the most sensitive marker of disease progression (r = -0.85, P < 0.0001). The mean annual rate of reduction in mean putamen Ki in the Parkinson's disease patients was 12.5% per annum, whereas the control group showed no significant change in Ki over a mean of 32 months follow up. The rate of progression was more rapid in the recent onset compared with the established disease group but this did not reach statistical significance. Assuming a linear progression for the entire group we estimate symptom onset at a mean putamen Ki 79% of normal with a mean preclinical period of 3.1 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Co-planar stereotaxic atlas of the human brain
Laitinen, L. (1989) · Clinical Neurology and Neurosurgery · doi:10.1016/0303-8467(89)90128-5 · Cited by 7,565
Practical Statistics for Medical Research.
Bartko, J. J., & Altman, D. G. (1992) · Journal of the American Statistical Association · doi:10.2307/2290246 · Cited by 4,797
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Parkinsonism: Onset, progression, and mortality
Hoehn, M., & Yahr, M. (2011) · Neurology · doi:10.1212/01.wnl.0000405146.06300.91 · Cited by 1,061
Rate of cell death in parkinsonism indicates active neuropathological process
McGeer, P. L., Itagaki, S., Akiyama, H., & McGeer, E. G. (1988) · Annals of Neurology · doi:10.1002/ana.410240415 · Cited by 556
The relevance of the Lewy Body to the pathogenesis of idiopathic Parkinson's disease
Lees, A. J. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302969 · Cited by 491
BROOKS, D. J., SALMON, E. P., MATHIAS, C. J., QUINN, N., LEENDERS, K. L., BANNISTER, R., MARSDEN, C. D., & FRACKOWIAK, R. S. J. (1990) · Brain · doi:10.1093/brain/113.5.1539 · Cited by 256
Self-citation
Cited by
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,810
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Self-citationIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Self-citationDescription of Parkinson's Disease as a Clinical Syndrome
FAHN, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07458.x · Cited by 977
The diagnosis of Parkinson’s disease
Tolosa, E., Wenning, G., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70285-4 · Cited by 902
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Self-citationAn algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Lee, C. S., Samii, A., Sossi, V., Ruth, T. J., Schulzer, M., Holden, J. E., Wudel, J., Pal, P. K., De La Fuente-Fernandez, R., Calne, D. B., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4<493::aid-ana13>3.0.co;2-4 · Cited by 580
Why Don't We Move Faster? Parkinson's Disease, Movement Vigor, and Implicit Motivation
Mazzoni, P., Hristova, A., & Krakauer, J. W. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0264-07.2007 · Cited by 557
Prospects for new restorative and neuroprotective treatments in Parkinson's disease
Dunnett, S. B., & Björklund, A. (1999) · Nature · doi:10.1038/399a032 · Cited by 537
Contrasting acute and slow-growing lesions: a new door to brain plasticity
Desmurget, M., Bonnetblanc, F., & Duffau, H. (2006) · Brain · doi:10.1093/brain/awl300 · Cited by 515
Morrish, P. K., Rakshi, J. S., Bailey, D. L., Sawle, G. V., & Brooks, D. J. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.314 · Cited by 510
Self-citationBezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guilloteau, D., Crossman, A. R., Bioulac, B., Brotchie, J. M., & Gross, C. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06853.2001 · Cited by 483
Medical records documentation of constipation preceding Parkinson disease: A case-control study
Savica, R., Carlin, J. M., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., Maraganore, D. M., Bharucha, A. E., & Rocca, W. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34af5 · Cited by 430
Kirik, D., Rosenblad, C., Björklund, A., & Mandel, R. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04686.2000 · Cited by 428
Menstrual cycle effects on cortical excitability
Smith, M. J., Keel, J. C., Greenberg, B. D., Adams, L. F., Schmidt, P. J., Rubinow, D. A., & Wassermann, E. M. (1999) · Neurology · doi:10.1212/wnl.53.9.2069 · Cited by 394
REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century
Claassen, D. O., Josephs, K. A., Ahlskog, J. E., Silber, M. H., Tippmann-Peikert, M., & Boeve, B. F. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ec7fac · Cited by 392
Epidemiology of Parkinson’s disease
Alves, G., Forsaa, E. B., Pedersen, K. F., Dreetz Gjerstad, M., & Larsen, J. P. (2008) · Journal of Neurology · doi:10.1007/s00415-008-5004-3 · Cited by 363
Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
Bezard, E., Gross, C. E., & Brotchie, J. M. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00038-9 · Cited by 350
Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
Fahn, S., & and the Parkinson Study Group (2005) · Journal of Neurology · doi:10.1007/s00415-005-4008-5 · Cited by 347
Biomarkers and surrogate markers: An FDA perspective
Katz, R. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.189 · Cited by 347
[ 123 I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression
Marek, K., Innis, R., van Dyck, C., Fussell, B., Early, M., Eberly, S., Oakes, D., & Seibyl, J. (2001) · Neurology · doi:10.1212/wnl.57.11.2089 · Cited by 347
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough
Lang, A. E., & Obeso, J. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00740-9 · Cited by 345
When Does Parkinson Disease Start?
Savica, R., Rocca, W. A., & Ahlskog, J. E. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.135 · Cited by 312
Vulnerability of the nigrostriatal system as detected by transcranial ultrasound
Berg, D., Becker, G., Zeiler, B., Tucha, O., Hofmann, E., Preier, M., Benz, P., Jost, W., Reiners, K., & Lange, K. W. (1999) · Neurology · doi:10.1212/wnl.53.5.1026 · Cited by 312
The role of DAT-SPECT in movement disorders
Kagi, G., Bhatia, K. P., & Tolosa, E. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.157370 · Cited by 311
Progression of Parkinson's disease in the clinical phase: potential markers
Maetzler, W., Liepelt, I., & Berg, D. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70291-1 · Cited by 305
Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes
Powers, K. M., Smith-Weller, T., Franklin, G. M., Longstreth, W. T., Swanson, P. D., & Checkoway, H. (2003) · Neurology · doi:10.1212/01.wnl.0000068021.13945.7f · Cited by 268
Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia
Cenci, M. A. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.005 · Cited by 265
Nandhagopal, R., Kuramoto, L., Schulzer, M., Mak, E., Cragg, J., Lee, C. S., McKenzie, J., McCormick, S., Samii, A., Troiano, A., et al. (2009) · Brain · doi:10.1093/brain/awp209 · Cited by 259
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease
Bohnen, N. I., Albm, R. L., Koeppe, R. A., Wernette, K. A., Kilbourn, M. R., Minoshima, S., & Frey, K. A. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600276 · Cited by 254
Levodopa in the treatment of Parkinson's disease
Schapira, A. H. V., Emre, M., Jenner, P., & Poewe, W. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02697.x · Cited by 231
Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182
Cell Survival and Clinical Outcome Following Intrastriatal Transplantation in Parkinson Disease
Hagell, P., & Brundin, P. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.741 · Cited by 174
NEUROIMAGING AND NEUROPSYCHOLOGY OF THE STRIATUM
Rauch, S. L., & Savage, C. R. (1997) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70343-9 · Cited by 148
Progression of monoaminergic dysfunction in parkinson's disease: a longitudinal 18f-dopa pet study
Pavese, N., Rivero-Bosch, M., Lewis, S. J., Whone, A. L., & Brooks, D. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.012 · Cited by 145
Self-citationDietary fats, cholesterol and iron as risk factors for Parkinson's disease
Powers, K. M., Smith-Weller, T., Franklin, G. M., Longstreth, W. T., Swanson, P. D., & Checkoway, H. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.03.002 · Cited by 100
Onset pattern of nigrostriatal denervation in early Parkinson’s disease
Pineda-Pardo, J. A., Sánchez-Ferro, Á., Monje, M. H. G., Pavese, N., & Obeso, J. A. (2022) · Brain · doi:10.1093/brain/awab378 · Cited by 51
Hall, H., Cuellar-Baena, S., Dahlberg, C., in’t Zandt, R., Denisov, V., & Kirik, D. (2011) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2011_166 · Cited by 17
Correlation of Parkinson's disease severity and duration with123I-FP-CIT SPECT striatal uptake
Benamer, H. T. S., Patterson, J., Wyper, D. J., Hadley, D. M., Macphee, G. J. A., & Grosset, D. G. (2000) · Movement Disorders · doi:10.1002/1531-8257(200007)15:4<692::aid-mds1014>3.0.co;2-v
Metadata
- Authors
- Morrish, P. K., Sawle, G. V., & Brooks, D. J.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 1996
- Volume
- 119
- Issue
- 2
- Pages
- 585-591
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2126384757
- Cited by
- 366
- References
- 14
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.